Logout Login Cart iconShop Contact Sales

Search

Filters

Content Type

Products

Clear Filters

Search Results for "华东重机 客户名单 新加坡PSA DP World 2025"

Looking for quality documents?
event icon
Antibody–Drug Conjugate Manufacturing: Driving Process Productivity and Reducing Risk
In this webinar, Field Applications Scientists Zoltán Gulyás and Nigel Herbert discuss how innovative technologies can help ADC manufacturers overcome common process hurdles. Through three real-world case studies, you’ll learn how to: Accelerate processing time and minimize risk to product and operators during tangential flow filtration (TFF) Maintain product consistency and operator safety while minimizing extractables and leachables. Drive process efficiency and reduce turnaround time with accurate, real-time DAR measurement
external link icon
Repligen Appoints Carrie Eglinton Manner to Board of Directors
WALTHAM, Mass., June 15, 2020 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN) today announced the appointment of healthcare industry executive Carrie Eglinton Manner to its Board of Directors. Ms. Eglinton Manner brings to the director role over 23 years of leadership experience across multiple disciplines. She currently serves as Senior Vice President, Advanced Diagnostics at Quest Diagnostics (NYSE:DGX), the world’s leading provider of diagnostic information services, which she joined in 2017. Prior to Quest, Ms. Eglinton Manner held various roles of increasing scope and responsibility over a period of 20 years at GE Healthcare (NYSE:GE). From 2009 through 2016, she served as President & CEO of four distinct GE Healthcare global businesses in the areas of diagnostic imaging, lab services and medical devices, ranging in size from approximately $150 million to $3 billion in revenue. “We are truly pleased to welcome Carrie as a director to our Board,” said Karen A. Dawes,
external link icon
Repligen to Present at 37th Annual J.P. Morgan Healthcare Conference
WALTHAM, Mass., Jan. 03, 2019 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will present at the 37 th Annual J.P. Morgan Healthcare conference being held January 7-10 at the Westin St. Francis in San Francisco.  Tony J. Hunt, President and Chief Executive Officer, will make a formal presentation on Tuesday, January 8, at 5:30 p.m. PST.

A live webcast of the presentation will be accessible through the Investor Events section of the Company’s website, and will be available for replay for a limited period of time following the conference event.

About Repligen Corporation
Repligen Corporation (NASDAQ:RGEN) is a bioprocessing-focused company that develops and commercializes highly innovative products that deliver cost and process efficiencies to biological drug manufacturers worldwide. Our portfolio includes protein products (Protein A affinity
external link icon
Repligen Announces Analyst Day and Webcast
WALTHAM, Mass., Sept. 15, 2017 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN) today announced that the Company will host an institutional investor and analyst meeting on Friday, September 29, 2017 in New York City from 7:30 a.m.-10:00 a.m. (ET). The event theme, Bioprocessing Industry Trends and Growth Drivers, will be discussed by Repligen management and outside expert Howard Levine, Ph.D., founder and President of BioProcess Technology Consultants.  A live webcast of the event will be accessible through the  Investor Relations section of Repligen’s website. This webcast will be archived for a period of time following the live event. About Repligen Corporation
Repligen Corporation (NASDAQ:RGEN) is a global bioprocessing company that develops and commercializes highly innovative products that deliver cost and process efficiencies to biological drug manufacturers worldwide. Our portfolio includes protein products (Protein A affinity ligands, cell culture growth
external link icon
Repligen Receives Milestone Payment From Pfizer
WALTHAM, Mass., Jan. 8, 2015 (GLOBE NEWSWIRE) - Repligen Corporation (Nasdaq:RGEN) announced today that on December 30, 2014, it received a $1 million milestone payment from Pfizer, Inc. under the terms of the companies' exclusive worldwide licensing agreement (the "Agreement") for the development of compounds to potentially treat spinal muscular atrophy (SMA), a neuromuscular disease that typically presents in children under age two. Since announcing the Agreement in January 2013, Repligen has received $7 million in upfront and milestone payments. Repligen remains eligible to receive up to $63 million in additional performance-based milestone payments, as well as royalties on any future sales of compounds developed under the Agreement. 2014 Revenue Repligen also today reported preliminary, unaudited total revenue of $63-$63.5 million for the fiscal year ended December 31, 2014. This total revenue figure is comprised of approximately $3 million in revenue from out-licensed therapeutic
external link icon
Repligen to Present at Stephens Inc. Fall Investment Conference
WALTHAM, Mass., Nov. 5, 2014 (GLOBE NEWSWIRE) - Repligen Corporation (Nasdaq:RGEN) today announced that Walter C. Herlihy, Ph.D., President and Chief Executive Officer, will present at the Stephens Fall Investment Conference on Wednesday, November 12 at 10:00 a.m. EST. The conference will be held at the New York Palace Hotel in New York City. An audio-only webcast of Dr. Herlihy's remarks and discussion with the audience will be accessible at the time of the presentation through the Investor Events section of Company's website. A replay of this webcast will also be accessible for a period of time following the event. About Repligen Corporation Repligen Corporation (Nasdaq:RGEN) is a life sciences company focused on the development and commercialization of high-value consumable products used in the process of manufacturing biological drugs. Our bioprocessing products are sold to major life sciences and biopharmaceutical companies worldwide. We are the leading manufacturer of Protein A
external link icon
Repligen to Present at the Stifel Healthcare Conference 2013
WALTHAM, Mass., Sept. 4, 2013 (GLOBE NEWSWIRE) - Repligen Corporation (Nasdaq:RGEN) today announced that Walter C. Herlihy, Ph.D., President and Chief Executive Officer, will present an overview of the Company at the Stifel Healthcare Conference on Wednesday, September 11, 2013 at 3:50 p.m. EDT. The annual conference will take place September 11-12 at the Four Seasons Hotel in Boston. The Repligen presentation will be webcast live and can be accessed through the Investors section of Company's website at www.repligen.com . The webcast and slide presentation will also be archived for a period of time on the Company's website. About Repligen Corporation Repligen Corporation (Nasdaq:RGEN) is a life sciences company focused on the development, production and commercialization of high-value consumable products used in the process of manufacturing biological drugs. Our bioprocessing products are sold to major life sciences and biopharmaceutical companies worldwide. We are a leading
external link icon
Repligen Receives First Milestone Payment From Pfizer Under Licensing Agreement for Spinal Muscular Atrophy Program
WALTHAM, Mass., Sept. 4, 2013 (GLOBE NEWSWIRE) - Repligen Corporation (Nasdaq:RGEN) announced today that it has received a $1 million milestone payment from Pfizer, Inc. under the terms of the companies' exclusive worldwide licensing agreement (the "Agreement") for the development of compounds to treat spinal muscular atrophy (SMA). This first milestone payment was triggered by completion of specific program activities and coincides with the successful completion of all transition obligations by Repligen. Repligen announced the Agreement in January of this year, at which time it received an upfront payment of $5 million. Repligen remains eligible to receive up to $64 million in additional success-based milestone payments, as well as royalties on any future sales of compounds developed under the Agreement. "Consistent with our strategic decision last August to focus on building Repligen's bioprocessing business while scaling back our investment in therapeutics, we out-licensed the SMA
external link icon
Repligen Announces Licensing Agreement with Pfizer for Spinal Muscular Atrophy Program
Repligen Corporation (NASDAQ:RGEN) announced today that it has entered into an exclusive worldwide licensing agreement with Pfizer Inc. to advance Repligen’s spinal muscular atrophy (SMA) program, originally in-licensed from Families of SMA (FSMA). The SMA program includes RG3039, a small molecule drug candidate in clinical development for SMA, as well as backup compounds and enabling technologies. Under the terms of the agreement, Repligen is entitled to receive up to $70 million from Pfizer, commencing with an upfront payment of $5 million and total potential future milestone payments of up to $65 million as well as royalties on any future sales of SMA compounds developed under the agreement. SMA is an orphan neurodegenerative genetic disease that presents early in life. “This agreement is consistent with the strategic decision we announced in August 2012 to focus Repligen’s internal efforts on the growth of our bioprocessing business, while seeking external partners for our
external link icon
Repligen to Present at Jefferies 2019 Healthcare Conference
WALTHAM, Mass., June 04, 2019 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that Jon K. Snodgres, Chief Financial Officer, will present at the Jefferies 2019 Global Healthcare Conference on Thursday, June 6 at 8:30 a.m. EDT.
A live audio webcast of the presentation will be accessible through the Investor Events section of the Company’s website, and will be available for replay for a limited period of time following the conference event. About Repligen Corporation
Repligen Corporation (NASDAQ:RGEN) is a global bioprocessing company that develops and commercializes highly innovative products that deliver cost and process efficiencies to biological drug manufacturers worldwide. Our portfolio includes filtration products (including XCell™ ATF, TangenX™ SIUS™ TFF and Spectrum KrosFlo™ TFF filters and systems), chromatography products (OPUS® pre-packed columns, chromatography resins,